You are here

Structural Heart

 

After receiving reports regarding reduced leaflet motion in some bioprosthetic aortic valves, the FDA announced on Oct. 5 that the agency is working with the American College of Cardiology, the Society of Thoracic Surgeons and device manufacturers to design clinical studies to evaluate the situation.

 

Recent Headlines

Same-day Discharge: Taking Pause over TAVR’s Milestone

One morning last year, a patient checked into a hospital in Canada as the first TAVR case of the day. 

FDA investigates reports of reduced leaflet motion in bioprosthetic aortic valves

After receiving reports regarding reduced leaflet motion in some bioprosthetic aortic valves, the FDA announced on Oct. 5 that the agency is working with the American College of Cardiology, the Society of Thoracic Surgeons and device manufacturers to design clinical studies to evaluate the situation.

Medtronic agrees to acquire privately-held TMVR device manufacturer

Medtronic agreed to acquire Twelve, a private medical device company that is developing a transcatheter mitral valve replacement (TMVR) device. The $458 million transaction is expected to close in October, according to a Medtronic news release.

Medtronic recalls EnVeo R loading systems

Medtronic recalled 6,912 units of the EnVeo R loading systems after receiving two reports of particulates in packaged kits and six reports of particulates in the loading bath during valve loading as of July 6.

Abbott commits to mitral valve disease treatments with two transactions

With two transactions on July 30, Abbott strengthened its structural heart business and emphasized its focus on treatments for mitral valve disease.

After 2 years, low stroke rates in TAVR patients

Fewer than six percent of patients who underwent transcatheter aortic valve replacement (TAVR) with the CoreValve device had strokes within two years of the procedure, according to a recent study. Researchers mentioned the 5.6 percent overall stroke rate was relatively low considering all patients were high-risk and had symptomatic aortic stenosis.

The Lowdown on TAVR: As Risk Drops, Expectations Rise

The prevailing wisdom is that transcatheter aortic valve replacement (TAVR) will waltz into the intermediate-risk category and then skip over to low-risk patients with severe aortic stenosis. 

TAVR’s Traditions & Transitions

Transcatheter aortic valve replacement (TAVR) has progressed at lightning speed. Some cardiologists now debate what may be getting lost amid this rapid change.

Moving TAVR forward

We expect the Supreme Court to act, at least once it commits to a case. The FDA, that’s another thing. But the FDA has been on a relative tear this month with nearly back-to-back approvals of two different transcatheter aortic valve replacement (TAVR) systems.

FDA waves in first retrievable, repositionable TAVR device

The FDA approved Medtronic’s CoreValve Evolut R device on June 23, giving physicians in the U.S. who perform transcatheter aortic valve replacement (TAVR) procedures the ability to recapture and reposition a valve during implantation.

Pages